Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model
about
HCV Kinetic Models and Their Implications in Drug DevelopmentViral kinetic modeling: state of the artQuantification of viral infection dynamics in animal experimentsModelling hepatitis C therapy--predicting effects of treatmentA quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivityA new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutantsA hepatitis C virus infection model with time-varying drug effectiveness: solution and analysisImprovement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimateInferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes.Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapyA pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic SHIV strain.A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins.Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection.Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.Duration of SHIV production by infected cells is not exponentially distributed: Implications for estimates of infection parameters and antiviral efficacy.Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.Multiscale modelling in immunology: a review.Pharmacodynamic models of age-structured cell populations.The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?Multiscale modeling of virus replication and spread.Consolidation of molecular testing in clinical virology.A complete categorization of multiscale models of infectious disease systems.Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs.3D Spatially Resolved Models of the Intracellular Dynamics of the Hepatitis C Genome Replication Cycle.Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor.A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents.A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis and Implications.Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale ModelingSuperinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence
P2860
Q26801602-FBAE644F-A6B9-49C3-939B-FA50B67DC8FFQ26824655-00AC9C52-B0B8-4F78-9F06-E4664AA47EE3Q26824804-2E08006A-8EC9-49C4-9220-E64B1502E2E2Q26864673-C788917F-69C3-44DC-8664-BA8C72461499Q28537708-5A9642C6-EE4A-41B7-B74E-A4B74B68F304Q28541048-5D670542-7E5A-4E4C-B0C6-B9636E732F5DQ28541682-3BC766EC-10AD-4AC8-94BB-FCD21B6C6211Q33703634-C8821ED3-A051-427C-80B7-D7BC85253E5DQ33794371-DD034C34-58B5-4276-8F24-080E616448C1Q34504820-81D2FFED-9BE7-40C6-918A-BDD650F82C96Q34675037-CB63575D-5261-4236-AFB8-5FCA208FD899Q35449696-67CA025D-3D98-4C7A-BC12-AF78A6467BA5Q35633691-B1E8F8F2-859D-4FD4-8430-054E754FBF8BQ36387986-96CD5982-BCD3-466E-8B8A-969257B2A562Q36889376-6C4F3F70-EEF9-4286-B57D-6443F1D0DBCAQ36921042-8926805E-3FBC-405C-A02C-269208B84C86Q37138516-C5504599-B035-4136-82E2-CA3F03A62A77Q37368417-8F2174F7-ABB5-4EE5-8BEC-EB34B2DD1156Q37644303-63F88B7C-38C8-433C-97EB-C801AEF1D651Q38375284-2626E758-13CD-485C-9489-EBC7FC01E107Q38391515-7C8EB1A2-6BC4-4AFD-987A-BCAC225EC940Q38588105-F4B8ED56-D07B-4647-8A2C-EAEE03665C1EQ38634755-C234D2F4-BB5C-442C-AED9-6161289760F6Q38733905-B937241E-AFB7-421E-B6CC-B66B93F685F2Q38779627-1E6395D4-861D-4937-9795-B4FCBD031BA0Q40076329-9F285B7A-BE8E-4634-AC0D-19DD3889A1BEQ41727459-26972374-868A-44A1-88F5-6BA7F8031424Q41925291-C4FD1696-1B55-4517-BC74-A65D2D84DB7AQ41950293-00EC6E13-72CA-43A2-9978-23C7CCAC2465Q47556299-50709C15-A812-419C-A1B9-D9EE46F01F48Q52579185-BE088E41-1740-426C-8EB0-904BA4885669Q52589911-F08995FE-2AEF-448F-B804-A8D2622D7546Q54254238-B55F998A-C2A9-49FF-830F-EF8D0C581878Q56000943-DF3A3692-1C23-4BDA-9863-5D8919D850ACQ56398203-D5E912B7-CA61-4107-9A1F-2930DDD3AF9E
P2860
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Analysis of hepatitis C virus ...... revir using a multiscale model
@ast
Analysis of hepatitis C virus ...... revir using a multiscale model
@en
Analysis of hepatitis C virus ...... revir using a multiscale model
@nl
type
label
Analysis of hepatitis C virus ...... revir using a multiscale model
@ast
Analysis of hepatitis C virus ...... revir using a multiscale model
@en
Analysis of hepatitis C virus ...... revir using a multiscale model
@nl
prefLabel
Analysis of hepatitis C virus ...... revir using a multiscale model
@ast
Analysis of hepatitis C virus ...... revir using a multiscale model
@en
Analysis of hepatitis C virus ...... revir using a multiscale model
@nl
P2093
P2860
P1476
Analysis of hepatitis C virus ...... revir using a multiscale model
@en
P2093
Daniel J Coffield
Harel Dahari
Libin Rong
Micha Levi
Patrick Smith
P2860
P304
P356
10.1371/JOURNAL.PCBI.1002959
P577
2013-03-14T00:00:00Z